NASDAQ$IMCR
Immunocore Holdings plc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Immunocore reported Q1 2026 with $106.7M revenue, net income of $13M, and diluted EPS of $0.25.
For the period ended 2026-03-31, Immunocore reported $106.7M revenue. KIMMTRAK net revenue $106.7M (+14% YoY). Net income $13.0M vs $5.0M; diluted EPS $0.25. Cash and marketable securities of roughly $745M at quarter-end. No formal EPS guidance; pipeline and KIMMTRAK geographic expansion discussed qualitatively.
- KIMMTRAK net revenue $106.7M (+14% YoY).
- Net income $13.0M vs $5.0M; diluted EPS $0.25.
- Cash and marketable securities of roughly $745M at quarter-end.
Headline financials
Revenue & EPS history
Immunocore · Revenue · Quarterly
$107M
Forward guidance
No formal EPS guidance; pipeline and KIMMTRAK geographic expansion discussed qualitatively.
Tailwinds
- Commercial revenue growth with operating profit.
- Strong liquidity supports R&D.
- Partner revenue from Medison and other distributors.
Headwinds
- Dependence on KIMMTRAK franchise.
- R&D spend remains elevated near $61M quarterly.
- FX and tax rate volatility.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
-0.3%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-1.2%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+8.3%
Q3 2023
Best reaction
-11.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.6% | +0.0% | -2.1% | |
| Q4 2025 | -4.8% | -3.0% | -12.6% | |
| Q3 2025 | -3.2% | +9.7% | +21.5% | |
| Q1 2025 | +6.3% | +5.3% | +32.8% | |
| Q4 2024 | +5.3% | -1.1% | +1.3% | |
| Q3 2024 | +4.0% | +5.0% | -4.5% | |
| Q2 2024 | +0.8% | +1.7% | -9.5% | |
| Q1 2024 | -1.9% | -6.6% | -31.7% | |
| Q4 2023 | -4.6% | -7.2% | -7.7% | |
| Q3 2023 | +8.3% | +4.6% | +15.8% | |
| Q2 2023 | -3.3% | -5.9% | -12.7% | |
| Q1 2023 | -1.5% | +3.2% | -4.6% | |
| Q4 2022 | -4.9% | -5.1% | -9.9% | |
| Q3 2022 | +2.9% | +13.7% | +9.3% | |
| Q2 2022 | +1.6% | +5.8% | -13.5% | |
| Q1 2022 | -11.0% | +2.7% | +1.4% | |
| Q4 2021 | -0.7% | +7.5% | +37.7% | |
| Q3 2021 | +0.4% | -0.2% | -21.3% | |
| Q2 2021 | -4.9% | -9.5% | -1.4% | |
| Q1 2021 | -1.5% | -9.4% | -5.3% | |
| Q4 2020 | +0.1% | +6.8% | -7.1% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro